NEPH (Nephros) Moat Score: 3/10 (As of Jul. 05, 2026)


NEPH Nephros Inc NEPH
63 GF Score
Price $3.40
GF Value $2.88
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Nephros Moat Score?

Nephros NEPH +0.89% 63 Moat Score is 3 as of Jul. 05, 2026. GuruFocus rates NEPH with a GF Score™ of 63/100 and a GF Value™ of $2.88 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 845 Medical Devices & Instruments companies, Nephros ranks better than 75.86% on this metric.

Nephros has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Nephros has No Moat: Nephros has a niche focus in water filtration but lacks significant market share and brand strength. It does not possess strong customer loyalty, regulatory barriers, or pricing power, resulting in a weak competitive position.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Nephros might have No Moat - Very weak/transient advantages.

Nephros  (NAS:NEPH) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Nephros Moat Score Related Terms

NEPH vs MLSS, RGNT, HBIO: Moat Score Comparison

For the Medical Instruments & Supplies subindustry, Nephros's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nephros Moat Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nephros's Moat Score distribution charts can be found below:

* The bar in red indicates where Nephros's Moat Score falls into.


NEPH
63GF Score
Nephros Inc NEPH
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Nephros (NEPH) has a Moat Score of 3 as of Jul. 05, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Nephros ranks #204 out of 845 companies in the Medical Devices & Instruments industry, placing it in the top 24.1%.
Is Nephros' Moat Score too high?
Nephros' current Moat Score is 3. Based on the distribution chart, Nephros ranks #204 out of 845 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Nephros has a GF Score™ of 63/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nephros' Moat Score compare to MLSS and RGNT?
According to the Medical Devices & Instruments industry distribution chart, Nephros ranks #204 out of 845 companies for Moat Score. This places Nephros in the top 24% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Devices & Instruments company?
A good Moat Score depends on the Medical Devices & Instruments industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Nephros's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nephros stock overvalued right now?
Based on GuruFocus' analysis, Nephros (NEPH) is currently considered Modestly Overvalued. The stock's GF Value™ is $2.88, compared to a current price of $3.40 — trading 18.1% above its estimated fair value. The current Moat Score is 3. Nephros' overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Nephros (NEPH), the current Moat Score is 3 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nephros (NEPH) Overvalued in 2026?

Based on GuruFocus' analysis, Nephros stock appears to be overvalued. The current stock price of $3.40 is trading 18.1% above its estimated GF Value™ of $2.88. GuruFocus considers Nephros to be Modestly Overvalued.

Key valuation signals for NEPH:

  • Moat Score: 3
  • GF Value™: $2.88 vs. price of $3.40 (18.1% above fair value)
  • GF Score™: 63/100 with 5 warning signs

No single metric tells the full story. See the NEPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nephros Business Description

Other Exchanges NPJP:Germany
Address 380 Lackawanna Place, South Orange, NJ, USA, 07079
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of revenue from product sales and a small amount from royalty revenue and other revenues.
63GF Score

Get the complete analysis for NEPH

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.40
Price
$2.88
GF Value